JOHN FANO SCHULTZE: Open Payments
NPI 1548363609 · FALLS CHURCH, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,008 in 47 payments from 21 companies in 2025. Trend: 2023 $50 · 2024 $1,047 · 2025 $1,008
Food & beverage: $1,008
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation | 7 | $135 |
| Merck Sharp & Dohme LLC | 5 | $119 |
| Novartis Pharmaceuticals Corporation | 6 | $113 |
| Astellas Pharma US Inc | 4 | $81 |
| PFIZER INC. | 3 | $70 |
| BeiGene USA, Inc. | 2 | $56 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Incyte Corporation | 2 | $43 |
| Lilly USA, LLC | 2 | $39 |
Products named: KEYTRUDA, REBLOZYL, KISQALI, TEVIMBRA, IBRANCE, Nubeqa, NINLARO, JAKAFI.
Industry payments across VA — which companies pay providers there.
